Wedbush Issues Pessimistic Forecast for KNSA Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities researchers at Wedbush decreased their FY2024 earnings per share estimates for Kiniksa Pharmaceuticals in a note issued to investors on Tuesday, October 29th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.42) for the year, down from their prior forecast of ($0.16). Wedbush has a “Outperform” rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.29) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.49 EPS, FY2026 earnings at $1.08 EPS and FY2027 earnings at $1.47 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The business’s quarterly revenue was up 67.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) earnings per share.

Several other research firms have also commented on KNSA. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $34.60.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock opened at $22.59 on Thursday. The company has a market capitalization of $1.61 billion, a PE ratio of -140.81 and a beta of 0.33. Kiniksa Pharmaceuticals has a one year low of $14.12 and a one year high of $28.15. The company’s 50 day moving average price is $25.57 and its two-hundred day moving average price is $22.42.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the sale, the chief operating officer now owns 116,975 shares of the company’s stock, valued at $2,923,205.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the transaction, the chief operating officer now owns 116,975 shares of the company’s stock, valued at $2,923,205.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,692 shares of company stock valued at $2,950,315 over the last three months. 54.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KNSA. CWM LLC lifted its position in shares of Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals in the first quarter worth about $71,000. nVerses Capital LLC bought a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $80,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. Finally, Lynx1 Capital Management LP bought a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth approximately $177,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.